Israel, Palestinians start to blame each other as talks look shaky

JERUSALEM, Oct. 3 (Xinhua) -- The latest round of the U.S.- sponsored direct peace talks between Israel and the Palestinians were stumbling as the two sides differed on the issue of whether or not Israel should extend its 10-month freeze on settlement construction in the West Bank after it ended last week.

Premier Wen urges EU recogniztion of China's market economy status

Chinese Premier Wen Jiabao delivers a speech at the Greek parliament in Athens on Oct. 3, 2010. (Xinhua/Rao Aimin)
ATHENS, Oct. 3 (Xinhua) -- Chinese Premier Wen Jiabao on Sunday urged the European Union to recognize China's full market economy status.

Chinese Premier makes five-point proposal on China

BEIJING, Oct. 3 (Xinhuanet) -- As Chinese Premier Wen Jiabao continues his three-day official visit to Greece, the two nations have clinched 13 deals and agreed to further deepen their comprehensive strategic partnership.

81-year-old man arrested for allegedly killing his 94-year-old roommate at an OC nursing home

LAGUNA HILLS, Calif. (AP) — Authorities say an 81-year-old man has been arrested on suspicion of murder for allegedly beating to death his 94-year-old roommate at an Orange County nursing home.

Brazil in Grip of Historic Vote

Photo: AP
Brazil's President Luiz Inacio Lula da Silva, right, smiles as Workers Party presidential candidate Dilma Rousseff gestures to supporters during a campaign rally in Sao Bernardo do Campo, outskirts of Sao Paulo, Brazil, Saturday, Oct. 2, 2010. Brazil will hold general elections on Oct. 3

Britain Raises Terror Warning; US Cautions Travelers

Britain on Sunday warned of the "high" threat of terrorism for its nationals in France and Germany, hours after the United States issued an alert cautioning Americans of the potential for terror attacks in Europe.

Germany Marks 20th Anniversary of Reunification | Europe | English

Photo: AP
German chancellor Angela Merkel arrives for celebrations marking the 20th anniversary of Germany's reunification in Bremen, northern Germany, Sunday Oct. 3, 2010

Yahoo News

• Pakistanis push trade, not just aid, after floods (AP)
• Brazil to pick successor for popular president (AP)
• US to warn Americans to be vigilant in Europe (AP)
• 2 NATO service members killed in Afghanistan (AP)
• DC rally shows support for struggling Democrats (AP)
• Missing pilots cast pall over balloon fiesta in US (AP)

» More News

Drug Trial News

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

1. October 2010 10:50

Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), AGS-003, demonstrated favorable progression-free survival (PFS) and safety in combination with sunitinib, based upon updated results from an ongoing Phase 2 trial. [More]

Be the first to rate this post

LSUHSC-S receives $3.9M NIDA grant for development of Embera's EMB-001 for cocaine dependence

1. October 2010 09:53

Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for addiction and obesity, announced today that the Louisiana State University Health Sciences Center (LSUHSC-S) has received a $3.9 million dollar grant from the National Institute on Drug Abuse (NIDA). The grant will support the next stages of development for Embera's drug candidate EMB-001 to treat cocaine dependence, as well as advance EMB-001 into clinical testing. [More]

Be the first to rate this post

AcelRx completes ARX-02 End-of-Phase 2 meeting with FDA for cancer breakthrough pain management system

1. October 2010 09:47

AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements. [More]

Be the first to rate this post

Benicar better than Cozaar in reducing blood pressure: Study

1. October 2010 09:36

New study results show that patients treated with Benicar® (olmesartan medoxomil) 40 mg once daily had significantly greater reductions in blood pressure and higher rates of goal attainment than patients receiving Cozaar® (losartan potassium) 100 mg once daily at week 8, according to findings of a new head-to-head study presented today at the late breaker session at the 23rd Scientific Meeting of the International Society of Hypertension (ISH) in Vancouver, Canada. [More]

Be the first to rate this post

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

1. October 2010 08:56

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor. [More]

Be the first to rate this post

FDA grants Emergent Fast Track Designation for AVP-21D9 anthrax monoclonal antibody development program

1. October 2010 08:44

Emergent BioSolutions Inc. announced today that its anthrax monoclonal antibody development program investigating AVP-21D9 for the treatment of inhalational anthrax has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). Emergent recently commenced a Phase I clinical trial for AVP-21D9, which is a fully human monoclonal antibody product candidate being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease. [More]

Be the first to rate this post

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

1. October 2010 06:26

Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population. [More]

Be the first to rate this post

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

1. October 2010 06:05

An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women. [More]

Be the first to rate this post

Achillion initiates ACH-1625 Phase II dosing for HCV infection

1. October 2010 05:09

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that the Company has initiated patient dosing in a Phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) infection. ACH-1625 is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication. The drug candidate was discovered and is being advanced by Achillion. [More]

Be the first to rate this post

NIH awards Polymedix $986,000 to develop defensin mimetic antimicrobial compounds for oral candidiasis

30. September 2010 09:33

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix. [More]

NASA - Multimedia - Video Gallery